Vagus Nerve Stimulation for Rheumatoid Arthritis：What Research Shows About This Emerging Treatment
Vagus nerve stimulation for rheumatoid arthritis is no longer only a laboratory idea, but the answer depends on the device. In the United States, the FDA approved the implanted SetPoint System in 2025 for a defined group of adults with moderately to severely active RA who have had an inadequate response, loss of response, or intolerance to biologic or targeted synthetic DMARDs. ([1]) That approval does not apply to every vagus nerve device, every person with RA, or ear-based consumer stimulation.
The research is still developing in important ways. The best evidence is for a surgically implanted system used under specialist care. Non-invasive ear-based vagus nerve stimulation, often called transcutaneous auricular VNS or taVNS, has shown mixed and early results. It should not be treated as interchangeable with the approved implant or as a substitute for a rheumatology treatment plan. ([2]) ([5])
Is Vagus Nerve Stimulation a Treatment for Rheumatoid Arthritis
For the specific FDA-approved indication, yes: the SetPoint System is an implanted vagus nerve stimulator intended for adults with moderately to severely active RA after inadequate response, loss of response, or intolerance to one or more biologic or targeted synthetic DMARDs. It is not a general over-the-counter treatment and requires a surgical implant next to the left cervical vagus nerve. ([1])
For other forms of VNS, the answer is more limited. A device being researched in a clinic, a neck-worn stimulator, and an ear-based wellness device have different stimulation sites, protocols, safety considerations, and evidence. “Vagus nerve stimulation” describes a category, not a single treatment. This distinction is the most useful starting point when reading claims about rheumatoid arthritis and the vagus nerve. ([2]) ([8])
Why Researchers Connected the Vagus Nerve and Rheumatoid Arthritis
RA is an immune-mediated inflammatory disease. Immune cells and inflammatory mediators such as tumor necrosis factor alpha (TNF-alpha) help drive synovitis, pain, and joint damage. Drug therapies target parts of this biology. VNS research asks a different question: can a neural circuit influence inflammatory signaling enough to improve disease activity in selected patients? ([3])
The proposed biology is often called the inflammatory reflex. Signals related to inflammation are integrated through neural pathways; vagus nerve activity is one part of the broader autonomic output that can influence cytokine production. That is not the same as “turning inflammation off.” It is a physiologic pathway that researchers are trying to modulate with carefully specified stimulation. ([3])
How Could VNS Influence Inflammatory Pathways
A simplified sequence looks like this: inflammatory signals are detected in the body, the brainstem and autonomic nervous system process relevant input, and downstream neural-immune signaling can affect immune-cell cytokine output. The cholinergic anti-inflammatory pathway is one proposed component of this communication. The pathway is scientifically plausible, but it does not mean every device that claims to “stimulate the vagus nerve” produces the same biological effect. ([3])
Dose, waveform, location, timing, participant population, and whether stimulation truly engages the intended nerve branch all matter. Those variables help explain why results from implanted VNS cannot simply be carried over to auricular stimulation. ([2]) ([8])
What Does the Research Show So Far
The pivotal RESET-RA trial offers the strongest current evidence for implanted therapy. In this double-blind, sham-controlled study, 242 participants with inadequate response or intolerance to advanced RA therapies received an implanted system and were assigned to active stimulation or sham stimulation for three months. The ACR20 response at three months was 35.2% with active stimulation and 24.2% with sham (P = 0.0209). After the controlled period, all participants received active stimulation, so later open-label results are useful but less suitable for a sham-controlled comparison. ([2])
Earlier studies helped establish the signal but were smaller. A 2016 implanted-device study reported reduced stimulated blood cytokine production and improvement in RA disease-activity measures. A 2020 randomized pilot in 14 people with multidrug-refractory RA was designed mainly around safety and feasibility; it supported larger sham-controlled evaluation but was too small to settle effectiveness on its own. ([3]) ([4])
|
Study
|
Approach
|
What it adds
|
Key limit
|
|
Tesser et al. 2026 [2]
|
Implanted VNS; 242-person randomized sham-controlled trial
|
Primary endpoint favored active stimulation at 3 months
|
Open-label follow-up cannot replace the controlled comparison
|
|
Koopman et al. 2016 [3]
|
Implanted VNS; early clinical study
|
Linked cytokine findings with disease-activity change
|
Small early study
|
|
Genovese et al. 2020 [4]
|
Miniaturized implanted VNS; 14-person pilot
|
Safety and feasibility data in refractory RA
|
Very small sample
|
|
Baker et al. 2023 [5]
|
Auricular VNS; 113-person sham-controlled trial
|
ACR20 at 12 weeks did not differ from sham
|
One protocol and device; not evidence for all ear-based approaches
|
|
Parikh et al. 2026 [8]
|
Home respiratory-gated taVNS; 12-person feasibility study
|
Home delivery and adherence were feasible
|
Single-arm, uncontrolled; not powered for efficacy
|
Table 1. Evidence map for vagus nerve stimulation approaches in RA. Study designs and devices are not interchangeable.
This mixed evidence is especially important for ear-based VNS. In the 2023 randomized, double-blind trial of 113 participants with active RA, the active and sham groups had similar ACR20 responses at week 12 (25.0% versus 26.9%; P = 0.823). A proof-of-concept study and small open-label studies can be useful for generating hypotheses, but they do not override a sham-controlled result. ([5]) ([6]) ([7])
There are also questions that a successful pivotal trial cannot answer by itself. Researchers still need longer real-world follow-up, clear estimates of who is most likely to benefit, and evidence on how the implanted system fits with medication changes over time. The FDA approval includes post-approval monitoring of safety, device performance, and clinical outcomes, a reminder that approval and continued evidence generation can happen together. ([1])
When reading a VNS headline, look beyond the phrase “reduced inflammation.” Ask whether the outcome was a laboratory marker, a patient-reported symptom, ACR20 response, disease activity score, imaging result, or a feasibility measure. Those endpoints answer different questions. A device can be practical to use at home without yet demonstrating disease-modifying benefit, while a surgically implanted system can have stronger efficacy data but a different risk and access profile. ([2]) ([8])
Implanted VNS and Ear Based taVNS Are Different
Implanted VNS for RA involves an outpatient surgical procedure to position a medical device near the cervical vagus nerve. The FDA-approved SetPoint System belongs in this category. Its indication is narrow, and implantation introduces procedure-related considerations that a specialist team should discuss. ([1]) ([2])
Ear-based taVNS uses electrodes at parts of the outer ear that may be supplied by the auricular branch of the vagus nerve. It avoids surgery, but “non-invasive” does not mean “proven for RA.” Protocols differ in ear site, frequency, pulse width, intensity, session length, and whether stimulation is synchronized to breathing. A 2026 home-based feasibility study enrolled 12 people with active RA. It found good session completion and no severe treatment-emergent adverse events, but its single-arm design cannot show that the device caused symptom or biomarker changes. ([8])
Figure 1. Participant kit used for home respiratory-gated taVNS in an RA feasibility study. Reproduced unchanged from Parikh et al. [8] under CC BY 4.0. This research prototype is not the FDA-approved implanted SetPoint System.
Can VNS Replace Rheumatoid Arthritis Medication
Do not stop, reduce, or delay prescribed RA medication because of VNS information online. RA treatment decisions typically use a treat-to-target approach and disease-modifying antirheumatic drugs remain central to management. Even the approved implanted VNS indication is for a selected population after insufficient response, loss of response, or intolerance to advanced therapies; it is not a blanket replacement for medication. ([1]) ([9])
A rheumatologist can put device options in context with disease activity, prior medication response, infection risk, imaging, pregnancy plans, surgery considerations, and access. If a clinician believes a person may be eligible for the approved system, the discussion should cover the procedure, expected monitoring, contraindications, and alternatives rather than treating VNS as a self-directed add-on. ([1])
What to Consider Before Trying a Vagus Nerve Device
-
Ask which exact device and stimulation site are being discussed. Evidence for a neck implant does not establish benefit for an ear device.
-
Ask whether the device is FDA-approved for RA, cleared or approved for another indication, or sold as a wellness product. These are different regulatory categories.
-
Look for a sham-controlled RA trial, not only studies in healthy participants or other conditions.
-
Review safety with a clinician, especially if you have an implanted electrical device, an upcoming procedure, active ear or skin problems, unexplained fainting, or a complex medical history.
-
Keep expectations specific: a wellness device may support a calming routine, but it should not be presented as a treatment for RA or a way to reduce inflammation.
Optional wellness context. ZenoWell Luna Plus is an ear-based, non-invasive stimulation device designed around autonomic-regulation and wellness routines. It is not the FDA-approved implanted RA therapy, and its use should not be interpreted as treatment for rheumatoid arthritis, a substitute for DMARDs, or a claim of reduced inflammation. People considering any device alongside RA care should review the plan with their rheumatology team.
Figure 2. Two-week protocol from a home respiratory-gated taVNS feasibility study in RA. Reproduced unchanged from Parikh et al. [8] under CC BY 4.0. The figure shows why feasibility work is not the same as a controlled efficacy trial.
Frequently Asked Questions
Does vagus nerve stimulation help rheumatoid arthritis
An implanted system has FDA approval for a specific group of adults with moderately to severely active RA after inadequate response, loss of response, or intolerance to biologic or targeted synthetic DMARDs. That evidence should not be generalized to every VNS device. Ear-based non-invasive VNS remains an active research area with mixed and limited RA-specific results. ([1]) ([5])
Is the vagus nerve connected to rheumatoid arthritis
Researchers study the connection because vagus nerve signaling is part of neural-immune communication that can influence cytokine production. The connection is biologically meaningful, but it does not make RA a condition that can be self-treated by generic “vagus nerve activation” techniques. ([3])
Is non-invasive VNS the same as implanted VNS
No. The FDA-approved RA system is implanted near the cervical vagus nerve. Ear-based taVNS is non-invasive and uses the outer ear. Their access routes, stimulation parameters, device oversight, and evidence bases differ. ([1]) ([8])
What is the main takeaway
Vagus nerve stimulation is a genuine new part of the RA treatment conversation, but precision matters. The approved implanted system is a specialist option for a defined treatment-experienced population. Non-invasive ear-based VNS is promising to study, yet it has not established the same RA treatment role. Use the device name, study design, and FDA indication to judge a claim, and make medication or procedure decisions with a rheumatology team. ([1]) ([2])
References
[1] U.S. Food and Drug Administration. Premarket Approval P240039: SetPoint System. Decision date July 30, 2025. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P240039
[2] Tesser JRP, Crowley AR, Box EJ, et al. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nature Medicine. 2026;32:369-378. doi:10.1038/s41591-025-04114-7.
[3] Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(29):8284-8289. doi:10.1073/pnas.1605635113.
[4] Genovese MC, Gaylis NB, Sikes D, et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatology. 2020;2(9):e527-e538. doi:10.1016/S2665-9913(20)30172-7.
[5] Baker MC, Kavanagh S, Cohen S, et al. A randomized, double-blind, sham-controlled, clinical trial of auricular vagus nerve stimulation for the treatment of active rheumatoid arthritis. Arthritis & Rheumatology. 2023;75(12):2107-2115. doi:10.1002/art.42637.
[6] Marsal S, Corominas H, de Agustín JJ, et al. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. Lancet Rheumatology. 2021;3(4):e262-e269. doi:10.1016/S2665-9913(20)30425-2.
[7] Drewes AM, et al. Short-term transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-inflammatory cytokines in rheumatoid arthritis: results of a pilot study. Scandinavian Journal of Rheumatology. 2021;50(1):20-27. doi:10.1080/03009742.2020.1764617.
[8] Parikh A, Lewis G, Almesfer F, et al. Home-based respiratory-gated transcutaneous auricular vagus nerve stimulation for rheumatoid arthritis: a feasibility study. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-08041-x. CC BY 4.0 figures reproduced unchanged in this article.
[9] Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021;73(7):924-939. doi:10.1002/acr.24596.
Related Posts
World Bipolar Day: How Vagus Nerve Stimulation May Support Better Mental Health
March 30 marks World Bipolar Day and also the birthday of Vincent van Gogh. This coincidence offers more than a symbolic moment. It invites us...
Oct 27 2026
Research Frontiers | Large Language Models for Longitudinal Symptom Tracking Following Vagus Nerve Stimulator Implantation
Introduction Following implantation of a vagus nerve stimulation (VNS) device, longitudinal changes in a patient's condition are generally documented in clinical notes. These notes...
Oct 23 2026
A Decade of SPARC and Over $350 Million in Funding: From Neural Mapping to Precision Vagus Nerve Modulation
Introduction Heartbeat, gastrointestinal motility, and bladder filling are all regulated by the autonomic nervous system. By influencing neural activity through electrical stimulation, researchers hope...
Oct 23 2026
Where to Place TENS Pads for Vagus Nerve Stimulation?
Where Should You Place TENS Pads for Vagus Nerve Stimulation? If you are looking for where to place TENS pads for vagus nerve stimulation,...
Oct 22 2026
Research Frontiers | Randomized Controlled Evidence That Transcutaneous Auricular Vagus Nerve Stimulation Reduces Rebound Pain After Arthroscopic Shoulder Surgery
Introduction Pain as the Block Wears Off Pain after arthroscopic shoulder surgery may be well controlled initially, only to intensify abruptly as the nerve...
Oct 13 2026
World Mental Health Day 2026: Theme and Meaningful Activities
World Mental Health Day 2026 takes place on Saturday, October 10. The official theme, shared by the World Health Organization (WHO) and the World...
Oct 10 2026
Research Frontiers｜Sleep Data From 330,000 People Link Healthy Sleep Patterns to Lower Dementia Risk
Midlife Sleep and Brain Health How do sleep habits in midlife relate to dementia risk more than a decade later? A study of over...
Oct 10 2026
